Suppr超能文献

PHII-7通过产生活性氧抑制白血病细胞系K562及其多药耐药对应细胞系K562/A02的细胞生长并诱导其凋亡。

PHII-7 inhibits cell growth and induces apoptosis in leukemia cell line K562 as well as its MDR- counterpart K562/A02 through producing reactive oxygen species.

作者信息

Peng Hongwei, Yuan Xiangfei, Shi Ruizan, Wei Xiaohua, Ren Simei, Yan Cihui, Ding Yahui, Lin Yang, Fan Dongmei, Yang Ming, Zhang Yanjun, Xiong Dongsheng

机构信息

State Key Laboratory of Experimental Hematology, Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, PR China; Department of Pharmacy, First affiliated Hospital of Nanchang University, Nanchang, Jiangxi, PR China.

出版信息

Eur J Pharmacol. 2013 Oct 15;718(1-3):459-68. doi: 10.1016/j.ejphar.2013.07.038. Epub 2013 Jul 30.

Abstract

Multidrug resistance (MDR) is a major obstacle that hinders the efficacy of chemotherapy in many human malignancies. PHII-7 is a derivative of indirubin, which was designed and synthesized by our laboratory. Our preliminary work indicated its potent antitumor activities in vitro and in vivo. Furthermore, based on the model of MDR cell line, we found its powerful effects in inhibiting the expression of P-glycoprotein (P-gp) and killing multidrug-resistant (MDR) cells with the detailed mechanism remained to be explored. Reactive oxygen species are known for high reactive activity as they possess unmatched electrons. In this study, we showed that PHII-7 generated equal reactive oxygen species in parental K562 and its counterpart MDR K562/A02 cells. Pre-incubation with thiol antioxidants glutathione or N-acetyl-cysteine(NAC) almost abolished the cytotoxicity of PHII-7. Moreover, NAC abrogated DNA damage, cell cycle arrests and apoptosis induced by PHII-7. Our results collectively indicated that reactive oxygen species production induced by PHII-7 contributed to both apoptosis and cell cycle arrets in MDR K562/A02 cells, thus extending our prior related findings. Notably, JNK phosphorylation was also induced by PHII-7 and pre-incubated of K562/A02 cells with NAC or inhibitor of JNK(SP006125) eliminated P-gp downregulation. Taken together, our results may provide a detailed biochemical basis for further clinical application of PHII-7.

摘要

多药耐药(MDR)是阻碍多种人类恶性肿瘤化疗疗效的主要障碍。PHII-7是靛玉红的衍生物,由我们实验室设计合成。我们的前期工作表明其在体外和体内均具有强大的抗肿瘤活性。此外,基于多药耐药细胞系模型,我们发现其在抑制P-糖蛋白(P-gp)表达和杀伤多药耐药(MDR)细胞方面具有强大作用,但其详细机制仍有待探索。活性氧因其具有未配对电子而具有高反应活性。在本研究中,我们发现PHII-7在亲本K562及其对应的MDR K562/A02细胞中产生等量的活性氧。用硫醇抗氧化剂谷胱甘肽或N-乙酰半胱氨酸(NAC)预孵育几乎消除了PHII-7的细胞毒性。此外,NAC消除了PHII-7诱导的DNA损伤、细胞周期阻滞和细胞凋亡。我们的结果共同表明,PHII-7诱导产生的活性氧导致MDR K562/A02细胞凋亡和细胞周期阻滞,从而扩展了我们之前的相关发现。值得注意的是,PHII-7还诱导JNK磷酸化,用NAC或JNK抑制剂(SP006125)预孵育K562/A02细胞可消除P-gp下调。综上所述,我们的结果可能为PHII-7的进一步临床应用提供详细的生化基础。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验